There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
See the full list of benefits that ESMO members enjoy including access to OncologyPRO, subscription to Annals of Oncology and reduced meeting registration fees
The ESMO membership booth will be at several oncology meetings in 2016. See where we'll be next!
We have a network of National and Regional Representatives who act as ambassadors of ESMO's mission in their respective country or region
All the important ESMO dates and deadlines in a single place - don't miss out, update your diaries now!
Primary Breast Cancer - ESO-ESMO Advanced Breast Cancer - BRCA in Breast Cancer
Cancers of Unknown Primary Site
High-Grade Malignant Glioma
Adrenal cancer - Thyroid cancer
Cancer of the Pancreas - Anal Cancer - Metastatic Colorectal Cancer - Oesophageal Cancer - Gastric Cancer - Early Colon Cancer - Familial Risk Colorectal Cancer - Rectal Cancer - Hepatocellular Carcinoma - Biliary Cancer
Cancer of the Prostate - Bladder Cancer - Renal Cell Carcinoma - Penile Carcinoma - Testicular Seminoma and Non-Seminoma
Endometrial Cancer - Gestational Trophoblastic-Disease - Newly-Diagnosed and Relapsed Epithelial Ovarian Carcinoma - Cervical Cancer - Non-Epithelial Ovarian Cancer
ALL - Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms - Hairy Cell Leukaemia - Peripheral T-Cell Lymphomas - Diffuse Large B Cell Lymphoma - CLL - Myelodysplastic Syndrome (MDS) - Hodgkin's Lymphoma - Mantle Cell Lymphoma - Follicular Lymphoma - Primary Cutaneous Lymphoma - Multiple Myeloma - AML in Adult Patients - Waldenstrom's Macroglobulinaemia - Gastric Marginal Zone Lymphoma of MALT Type - CML
Nasopharyngeal Cancer - Squamous-Cell Carcinoma of the Head and Neck
Malignant Pleural Mesothelioma - Thymic Epithelial Tumours - Metastatic Non-Small-Cell Lung Cancer - Early-Stage and Locally Advanced (non metastatic) Non-Small-Cell Lung Cancer - Small-Cell Lung Cancer
Neuroendocrine Bronchial and Thymic Tumours - Neuroendocrine Gastroenteropancreatic Tumours
Soft Tissue and Visceral Sarcomas - Bone Sarcomas - Gastrointestinal Stromal Tumours
Management of Oral and Gastrointestinal Mucosal Injury - Central Venous Access in Oncology - Treatment of Dyspnoea in Advanced Cancer Patients - Refractory Symptoms - Advanced Care Planning - Bone Health - Cancer, Pregnancy and Fertility - Chemotherapy Extravasation - Cardiovascular Toxicity - Cancer Pain - Venous Thromboembolism - Erythropoiesis Stimulating Agents in the Treatment of Anaemia - Prevention of Chemotherapy and Radiotherapy Induced Nausea and Vomiting - Febrile Neutropenia - Haematopoietic Growth Factors
Download the new version of our App with the latest Pocket Guidelines for professionals and Guides for Patients
To assist those using and/or evaluating the ESMO Guidelines, download the methodology here
Addressing the daily needs of ESMO young oncologists
Invest in your future and the future of cancer care. Learn more about our Oncology Fellowship Programme.
The latest oncology jobs can be found here, including information on how to post a job.
ESMO has developed a number of awards that recognise excellence in the field of oncology
ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology is now available in Serbian
The ESMO examination is a valuable assessment tool for practicing medical oncologists and for medical oncologists in training to assess their knowledge
If you've already sat the ESMO exam, then take a look at our CME opportunities.
Discover the results of the ESMO Survey on the challenges faced by female oncologists
An inspiring new programme for future ESMO leaders
An ESMO pre-selected listing of the most recent EU research funding opportunities
Relevant information and tools to guide you through various EU grant application procedures
A selection of funding organisations to assist you in your projects
What`s available in terms of clinical research training and educational events
Clear, relevant information on EU clinical trials and data protection legislation
Useful links to partners and tools for your research projects
General European grant scheme information highlighting the main objectives, available funding and target audiences
Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices
Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine
Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.
The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.
The ESMO Patient Advocacy Track encourages communication between patients, families, oncologists and healthcare professionals.
Medical oncology is included among the medical specialities covered by the European Commission Directive 2005/36/EC.
ESMO's political initiatives aim to promote the profession of medical oncology and keep cancer policy high on the European healthcare agenda.
ESMO position statements and recommendations can be downloaded here.
The ESMO Magnitude of Clinical Benefit Scale - promoting clear and unbiased communication about the benefit of cancer treatments
The objective of this ESMO-led study is to provide health authorities with data on the availability of licensed anti-neoplastic medicines
ESMO has endorsed the 'Prague Charter: Relieving suffering' set up by the European Association for Palliative Care (EAPC) & other organisations
ESMO seeks to eradicate cancer at its earliest stages through effective cancer prevention awareness and advocacy campaigns.
Rare Cancers Europe is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda.
Information about the EFPIA Disclosure Code which comes into effect 1 January 2015